Get the Stockscreener App
5.81
0.00%
0.00
After Hours:
5.81
Kamada Ltd stock is traded at $5.81, with a volume of 31,652.
It is up +0.00% in the last 24 hours and up +10.04% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$5.81
Open:
$5.78
24h Volume:
31,652
Relative Volume:
0.92
Market Cap:
$327.42M
Revenue:
$154.57M
Net Income/Loss:
$15.07M
P/E Ratio:
72.62
EPS:
0.08
Net Cash Flow:
$10.92M
1W Performance:
-0.17%
1M Performance:
+10.04%
6M Performance:
+9.62%
1Y Performance:
+21.80%
1-Day Range:
$5.675
$5.81
1-Week Range:
$5.675
$5.89
52-Week Range:
$4.60
$6.5291
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
5.81 | 327.42M | 154.57M | 15.07M | 10.92M | 0.08 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business - Simply Wall St
Alpha 1 Antitrypsin Deficiency Treatment Market Analysis By Top - openPR
HC Wainwright Issues Pessimistic Outlook for Kamada Earnings - MarketBeat
What is HC Wainwright’s Forecast for Kamada FY2024 Earnings? - Defense World
Alpha-1 Antitrypsin Deficiency Therapy Market 2024-2031 - openPR
HC Wainwright Forecasts Kamada's Q4 Earnings (NASDAQ:KMDA) - MarketBeat
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook - Investing.com India
Phoenix Financial Ltd. Increases Stake in Kamada Ltd. - GuruFocus.com
Kamada Ltd. (NASDAQ:KMDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Reven - GuruFocus.com
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ... - Yahoo Finance
Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market to Grow - openPR
Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart
Earnings call: Kamada Ltd. reports growth and raises EBITDA outlook By Investing.com - Investing.com Australia
Kamada: Q3 Earnings Snapshot - Barchart
Kamada reports Q3 EPS 7c, consensus 7c - TipRanks
Kamada’s Strong Growth and Strategic Expansion in 2024 - TipRanks
KMDAKamada Ltd Latest Stock News & Market Updates - StockTitan
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance - The Manila Times
Kamada Reports Continued Profitable Growth with Strong - GlobeNewswire
Kamada Q3 Revenue Surges 10% to $41.7M, Boosts EBITDA Guidance Amid Strong Growth | KMDA Stock News - StockTitan
Cystic Fibrosis Market Size to be Worth USD 55.4 Billion by 2032, with a Projected CAGR of 21.6% - WICZ
Report shares who was actually responsible for bringing Daichi Kamada to Crystal Palace - We Are Palace
Alpha 1 Lung Disease Market Growth Set to Surge Significantly by 2031 As Revealed In New Report - WhaTech
What fixtures Daichi Kamada will miss for Crystal Palace after red card in 2-0 Fulham defeat - We Are Palace
Kamada (KMDA) Scheduled to Post Earnings on Wednesday - MarketBeat
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times
Kamada Ltd. sets Q3 earnings call for November 13 - Investing.com India
Kamada to Release Q3 Financial Results Amid Global Expansion - TipRanks
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024 - The Manila Times
Kamada to Announce Third Quarter and Nine-Months Ended - GlobeNewswire
Kamada (KMDA) Sets Q3 2024 Earnings Call for November 13What to Expect | KMDA Stock News - StockTitan
Stratasys unveils new IoT platform for 3D printing operations By Investing.com - Investing.com South Africa
Kamada to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
Kamada to Present at Stifel Healthcare Conference - TipRanks
Earnings growth outpaced the 24% return delivered to Kamada (TLV:KMDA) shareholders over the last year - Simply Wall St
Blood Plasma Market to Grow by USD 15.9 Billion (2024-2028) as Innovative Solutions Address Global Blood Shortage; Report Highlights AI's Impact on Market TrendsTechnavio - The Malaysian Reserve
Global Healthcare & Medical Tourism News - Medical Tourism Magazine
Global Plasma Protein Therapeutics Market to Touch ~USD 40 Billion Mark by 2030 | DelveInsight - GlobeNewswire
What Jean-Philippe Mateta did after Daichi Kamada scored in Aston Villa 1-2 Crystal Palace, it was telling - We Are Palace
Kamada strike secures Quarter-Final spot - Holmesdale Online
Aston Villa 1-2 Crystal Palace: Daichi Kamada fires Eagles into last eight of Carabao Cupbut visitors lose - Daily Mail
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times
Alvotech to Report Financial Results for the First Nine - GlobeNewswire
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024 - The Manila Times
Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire
Kamada (NASDAQ:KMDA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Kamada Ltd. Announces 2024 Annual General Meeting - TipRanks
Alpha 1 Lung Disease Market Projected to Reach $19.93 Billion by 2031 with 19.33% CAGR - WhaTech
Kamada Ltd. (NASDAQ:KMDA) Short Interest Update - MarketBeat
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):